Angel, Luis F.School of Medicine |
| 9/2007 - Present | Associate Professor/Clinical and Associate Professor of Medicine | University of Texas Health Science Center at San Antonio, Medicine, San Antonio, TX |
| 1/2006 - Present | Medical Director of the Lung Transplant Program and Clinic Director | The University of Texas Health Science Center at San Antonio, Surgery and Medicine, San Antonio, TX |
| 8/2001 - Present | Director of Interventional Pulmonary and Interventional Pulmonary | The University of Texas Health Science Center at San Antonio, Surgery and Medicine, San Antonio, TX |
| Year | Degree | Discipline | Institution |
| 2001 | Clinical Fellowship | Interventional Pulmonology | Beth Israel Deaconess Medical Center, Harvard Medical School Boston , MA |
| 2000 | Clinical Fellowship | Pulmonary and Critical Care | The University of Texas Health Science Center at San Antonio San Antonio , TX |
| 1997 | Residency | Internal Medicine | The University of Texas Health Science Center at San Antonio San Antonio , TX |
| 1995 | Internship | Internal Medicine | The University of Texas Health Science Center at San Antonio San Antonio , TX |
| 1992 | MD | Medicine | Universidad Pontificia Bolivariana Medellin , Colombia |
| 1983 | BS | Bachiller Academico | Colegio Benedictino De Santa Maria Medelllin , Colombia |
Device Development/Invention- Involved in the development through start up company of medical devices for critical care patients, in particular focused in bringing into clinical practice new endotracheal tubes and an inferior vena cava filter for use in critical ill patients. |
Interventional Pulmonary- First fellow trained at the Beth Israel Deaconess Medical Center in Boston in interventional pulmonary. Developed the Interventional Pulmonary Program at the UTHSCSA and the University Health System. This program now is well recognized as the only interventional and advanced bronchoscopy program in South Texas. He introduced rigid bronchoscopy techniques, LASER resection, coagulation, cryotherapy and more recently the revolutionary techniques on endobronchial ultrasound. |
Lung Transplantation- The transplant program at the UTHSCSA has a long tradition and since 2001. The research and work with the management of potential lung donors has increased the volume and improved the results to have at this institution one of the best recognized programs in lung transplantation. We are involved in the national guidelines for donor management, evaluation of Antibody Mediated Rejection and recently developed a protocol to investigate gene activation during rejection. |
| Date | Description | Institution | # Students |
| 9/2001 - Present | Pulmonary and Critical Care Journal Club | UTHSCSA | 6 students |
| This is a monthly review of the 4-6 most important articles on pulmonary and critical care medicine with all the fellows. During this journal club Dr Angel does a scientific review of all the articles and has a discussion about the quality of the study and implications of each paper in our current practice. | |||
Journal Article |
| Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T, Angel LF. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: american college of chest physicians evidence-based clinical practice guidelines Chest 2012 Nov;142(5):1-111. |
| Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T, Angel LF. Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: american college of chest physicians evidence-based clinical practice guidelines Chest 2012 Nov;142(5):1284-1288. |
| Burguete SR, Levine SM, Restrepo MI, Angel LF, Levine DJ, Coalson JJ, Peters JI. Lung transplantation for Williams-Campbell syndrome with a probable familial association Respir Care 2012 Sep;57(9):1505-1508. |
| Peters JI, Stupka JE, Singh H, Rossrucker J, Angel LF, Melo J, Levine SM. Status asthmaticus in the medical intensive care unit: A 30-year experience Respir Med 2012 Mar;106(3):344-348. |
| Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic review of the use of retrievable inferior vena cava filters J Vasc Interv Radiol 2011 Nov;22(11):1522-1530. |
| Naik PM, Angel LF. Special issues in the management and selection of the donor for lung transplantation Semin Immunopathol 2011 Mar;33(2):201-210. |
| Angel LF, Pollack M, Levine D, Werner S, Coalson J. Post-transplant donor specific antibodies with or without positive C4d staining are correlated with poor lung transplant outcomes American Transplant Congress Annual Meeting 2009 May;. |
| Cadena J, Levine DJ, Angel LF, Maxwell PR, Brady R, Sanchez JF, Michalek JE, Levine SM, Restrepo MI. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness American Journal of Transplantation 2009 Jan;9(9):2085-2091. |
| Angel LF, Levine D, Abboud-Werner S, Pollack M, Coalson M, Levine S, Peters J, Johnson J, Calhoon J. The presence of HLA-Class II-DQ donor specific antibodies (DSA) in lung transplant recipients (LTR) even in the absence of other DSA and C4d staining is associated with severe histophathological changes and impaired graft survival Chest Annual Meeting Program Book 2009 Jan;. |
| Mulrow CD, Chiquette E, Angel L, Grimm R, Cornell J, Summerbell CD, Anagnostelis BB, Brand M, Angel LF. WITHDRAWN: Dieting to reduce body weight for controlling hypertension in adults Cochrane Database Syst Rev 2008 Oct;(4):000484-000484. |
Book Chapter |
| Angel LF, Levine SM. Critical Care of the Lung Transplant Recipient. In: Richard Irwin and James Rippe. Irwin and Rippes: Intensive Care Medicine, 7th Edition. 2011. p. 1957-1968. |
| Angel L, Levine D. Basic Therapeutic Techniques. In: Armin Ernst. Introduction to Bronchoscopy. Cambridge University Press; 2009. p. 142-151. |
Abstract |
| Pollack MS, Levine DJ, Abboud Werner SL, Coalson JJ, Angel LF. The Development, Frequent Spontaneous Resolution and Some Apparent Clinical Consequences of Donor Specific HLA Antibodies after Lung Transplantation; 2011 May. (Am J Transplantation). |
| Levine DJ, Coalson JJ, Pollack MS, Werner S, Babu RV, Levine SM, Johnson SB, Peters JI, Calhoon JH, De Armond DT, Angel LF. Detection of HLA-II-DQ donor-specific antibody (DSA) in lung transplant recipients (LTRS) is associated with severe histopathologic changes and impaired graft survival even in the absence of other DSAS and positive C4D-immunostaining; 2009 Oct. (Chest Meeting Abstracts). |
| Peters JI, Saad AR, Cline AM, Watts AB, Hsiung GE, Baisden CE, Levine DJ, Calhoon JH, Angel LF, Williams III R, Johnson SB. Nanoparticle tacrolimus inhalation in rat lung transplant model; 2008 Oct. (CHEST; vol. 134). |
| Levine DJ, Pollack MS, Coalson JJ, Johnson SB, Calhoon JH, Levine SM, Angel LF, Werner S. A Multifaceted Approach to Detect Antibody-Mediated Rejection in Lung Transplant Recipients; 2008 Oct. (CHEST; vol. 134). |
| Sanchez J, Angel LF, Levine DJ, Levine SM, Calhoon JH, Johnson SB, Duran P, Mortensen EM, Anzueto AR, Restrepo MI. Health Care-Associated Pneumonia (HCAP) Have Similar Mortality Rates Compared to Hospital-Acquired (HAP) and Ventilator-Associated Pneumonia (VAP) in Lung Transplant Recipients; 2008 Oct. (CHEST; vol. 132, no. 4). |
| Sanchez J, Angel LF, Levine DJ, Calhoon JH, Levine SM, Johnson SB, Mortensen EM, Anzueto AR, Restrepo MI. Sepsis Due To Pneumonia Is Associated With Higher Mortality In Lung Transplant Recipients; 2008 Oct. (CHEST; vol. 134). |
| Peters JI, Purvis T, Pollack MS, Angel LF, Williams III R. In vitro efficacy and in vivo safety of inhaled nanoparticles of tacrolimus; 2007 Oct. (Chest Meeting Abstracts; vol. 132). |
| Sanchez J, Angel LF, Levine DJ, Johnson SB, Michalek JE, Zarzabal LA, Sako E, Pelaez A, Mehta A, Calhoon J, Levine SM, Lyu D. Using Post-Lung Transplant FEV1 To Predict Survival in COPD Patients Undergoing Single Lung Transplantation (SLT); 2007 Oct. (CHEST; vol. 132). |
| Peters JI, Purvis T, Pollack M, Angel LF, Williams R III. In Vitro Efficacy and In Vivo Safety of Inhaled Nanoparticles of Tacrolimus; 2007 Aug. (CHEST). |
Editorial |
| Angel LF. The Value of Answering Simple Bronchoscopy Questions with Randomized Clinical Trials Chest 2012 Sep;142:551-552. |
| Levine SM, Angel LF. Is the lung allocation score working? A qualified: yes Chest 2009 Apr;135(4):890-892. |
Private |
|
| Funding Agency | Myogen, Inc |
| Title | ARIES-1: Ambrisentan in PAH - A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension |
| Status | Active |
| Period | 5/2007 - Present |
| Role | Co-Investigator |
| Grant Detail | Goal: New endothelin receptor antagonist drug for treatment of pulmonary arterial hypertension. To evaluate the safety and efficacy of ambrisentan in treatment of pulmonary arterial hypertension |
| Funding Agency | Alveolus, Inc. |
| Title | Clinical Investigation of the Safety and Efficacy of the Alveolus TM Tracheobronchial Stent for Airway Obstruction - A prospective, Historically Controlled Study |
| Status | Active |
| Period | 5/2004 - Present |
| Role | Principal Investigator |
| Grant Detail | Goal: Device to improve quality of life in non-operative candidate patients with malignant tumors blocking airway passages Evaluate the safety and efficacy of the Alvelus Tracheobronchial Stent of airway obstruction in subjects with non-operative malignant tumors. |
| Funding Agency | Emphasys, Inc. |
| Title | Endobronchial Valve for Emphysema Palliation Trial - VENT |
| Status | Active |
| Period | 6/2008 - Present |
| Role | Principal Investigator |
| Grant Detail | Goal: To relieve symptoms and improve quality of life of emphysema patients without surgical intervention Evaluate the safety and efficacy of the Emphasys Endobronchial Valve for Emphysema Palliation Trial (VENT) |